Detalhe da pesquisa
1.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet
; 403(10427): 632-644, 2024 Feb 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38246194
2.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 381(16): 1535-1546, 2019 10 17.
Artigo
Inglês
| MEDLINE | ID: mdl-31562797
3.
Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
Oncologist
; 26(9): e1633-e1643, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34101298
4.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(11): 1465-1477, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32961119
5.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med
; 377(19): 1824-1835, 2017 11 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28891423
6.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 377(14): 1345-1356, 2017 10 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28889792
7.
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Cancer
; 125(7): 1113-1123, 2019 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30690710
8.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med
; 373(1): 23-34, 2015 Jul 02.
Artigo
Inglês
| MEDLINE | ID: mdl-26027431
9.
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA.
Future Oncol
; 13(19): 1699-1710, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28605939
10.
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
J Clin Oncol
; 41(1): 75-85, 2023 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35867951
11.
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Eur J Cancer
; 173: 285-296, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35964471
12.
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
J Clin Oncol
; 40(2): 127-137, 2022 01 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34818112
13.
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
J Immunother Cancer
; 9(8)2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34452930
14.
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
PLoS One
; 16(4): e0248097, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33826614
15.
Molecularly targeted agents for renal cell carcinoma: the next generation.
Clin Adv Hematol Oncol
; 8(5): 357-60, 361-4, 2010 May.
Artigo
Inglês
| MEDLINE | ID: mdl-20551895
16.
Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy.
Cancer Med
; 9(20): 7381-7387, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32578965
17.
Renal cell carcinoma.
Curr Opin Oncol
; 21(3): 266-71, 2009 May.
Artigo
Inglês
| MEDLINE | ID: mdl-19339887
18.
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
Curr Oncol Rep
; 11(2): 94-101, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19216840
19.
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma.
Cancers (Basel)
; 11(11)2019 Oct 24.
Artigo
Inglês
| MEDLINE | ID: mdl-31653096
20.
Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article).
Medicine (Baltimore)
; 98(28): e16328, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-31305421